MethodSense, Inc.

MethodSense, Inc. is a regulatory and quality consulting firm specializing in medical device product development and commercialization. The company provides strategic guidance and execution support for FDA submissions, EU MDR compliance, and global regulatory pathways, backed by over 25 years of industry experience and more than 200 successful submissions.

The firm offers integrated services spanning regulatory strategy, quality management systems, submission preparation, and AI/ML compliance. Their proprietary LuminLogic platform provides cloud-based compliance management software for document control, audit readiness, and lifecycle management. MethodSense serves medical device companies from startup through scale-up stages, including support for venture capital and private equity portfolio companies.

Led by CEO Rita King, a recognized authority on FDA and EU regulatory affairs, the company has established expertise in complex technologies including neurology devices, diagnostics, robotics, and drug delivery systems. The firm's client portfolio includes companies that have achieved ISO 13485 certification, CE Marks, and are selling in international markets.

Choose MethodSense when regulatory strategy needs to align with business objectives—particularly for fundraising, M&A preparation, or market expansion. The firm embeds deeply with client teams rather than providing arm's-length advisory, evidenced by their participation in investor calls and hands-on support through human factors testing and audit preparation.

Expect a combination of strategic regulatory planning and tactical execution support, with the LuminLogic platform providing structure for ongoing compliance management. Their experience with complex technologies like AI/ML and robotics makes them particularly valuable for innovative device categories facing evolving regulatory requirements.

MethodSense exclusively serves the medical device and life science sectors, with specialized expertise in neurology, diagnostics, AI-enabled medical devices, surgical robotics, and drug delivery systems. The firm maintains deep knowledge of FDA regulatory pathways, EU MDR requirements, and ISO 13485 quality standards specific to medical device manufacturing.

Their healthcare focus extends beyond compliance to understanding investor requirements in the medtech space, enabling them to support portfolio companies for venture capital and private equity firms. The company's Elsa Resource Center demonstrates their commitment to helping clients navigate emerging FDA digital submission requirements specific to medical devices.

The ideal client is a venture-backed or growth-stage medical device company developing Class II or Class III devices, particularly those incorporating software, AI/ML, or novel technologies. Companies preparing for their first FDA submission, seeking to expand internationally, remediating regulatory gaps, or positioning for acquisition will find the most value in MethodSense's integrated approach to regulatory strategy and quality systems implementation.